Updated hourlyHourly refreshTue, Oct 27, 2026
Press Release Database
Recent press releases, indexed by topic.
Finance · Healthcare
ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announces that director Lionel Carnot will be resigning from the Board of Directors, effective today, after nearly a decade of dedicated service since 2017.
Sep 30 · 20:46·GlobeNewswire
AI · Biotech & pharma
The post How AI could help scientists find viruses to fight drug-resistant infections appeared first on Source.
Sep 30 · 20:01·Microsoft
Food & drink · Biotech & pharma
Now SSDP is mobilizing researchers, patients, students, and the public to fight the proposed scheduling of five tryptamines. Submit a public comment to the DEA by October 23 using SSDP’s easy-to-use public comment tool. WASHINGTON, D.C. – September 30, 2026 — A psychedelic drug granted Breakthrough Therapy designation by the U.S. Food and Drug […]
Sep 30 · 18:57·Presswire
Finance · Biotech & pharma
MORRISVILLE, N.C., Sept. 30, 2026 -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today issued an update regarding the litigation filed by United Therapeutics Corporation (UTHR) in the U.S. District Court for the District of Delaware (the Court) under the Hatch-Waxman Act concerning U.S. Patent No. 11,826,327 (‘327 patent) and the Company’s lead product, YUTREPIA® (treprostinil) inhalation powder.
Sep 30 · 17:20·GlobeNewswire
Healthcare · Biotech & pharma
NEW YORK, Sept. 30, 2026 -- Eating sweets while taking antibiotics may worsen the harm done by the drugs to the normal community of bacteria in the gut, a new study found. The work centers on the intestinal microbiome, which harbors bacterial species that co-evolved with...
Sep 30 · 15:11·PR Newswire
Finance · Healthcare
NEEDHAM, Mass., Sept. 30, 2026 -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the presentation of new biomarker data from its completed phase 3 clinical trial of aglatimagene besadenovec (aglatimagene) in patients with localized intermediate- to high-risk prostate cancer at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2026.
Sep 30 · 12:05·GlobeNewswire
Healthcare · Biotech & pharma
EBGLYSS monotherapy met its primary endpoint with more than half of patients achieving clear or almost clear skin on their hands and feet (HF-IGA...
Sep 30 · 12:03·Eli Lilly and Company
Automotive · Biotech & pharma
– Analysis shows YCANTH achieved complete clearance of molluscum contagiosum approximately 4 times faster than vehicle, regardless of disease duration –
Sep 30 · 12:00·GlobeNewswire
Finance · Healthcare
VANCOUVER, British Columbia, Sept. 30, 2026 -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced updated clinical data from the Phase 1b/2a RESOLVE study highlighting the long duration of response, high remission rates and tolerability of EP-104GI for the treatment of Eosinophilic Esophagitis (“EoE”).
Sep 30 · 12:00·GlobeNewswire
Healthcare · Biotech & pharma
Global Phase 2/3 trial evaluates SIL204 in combination with standard chemotherapy in patients with locally advanced pancreatic cancer
Sep 30 · 12:00·GlobeNewswire
Biotech & pharma
Detailed findings, to be presented in a short oral presentation, demonstrated an approximately 11- to 12-day half-life and dose-proportional...
Sep 30 · 09:45·AbbVie
Healthcare · Travel
The global dental equipment market is projected to grow from USD 8.31 billion in 2026 to USD 11.48 billion by 2031, registering a 5.5% CAGR. Growth is driven by rising oral health disorders, demand for cosmetic and preventive dentistry, dental tourism, and adoption of digital imaging, CAD/CAM, intraoral scanners, laser dentistry, and 3D printing. Therapeutic dental equipment will hold the largest market share, while hospitals and clinics remain the leading end users. The US is expected to record North America’s fastest growth. Key players include Dentsply Sirona, Planmeca, Align Technology, Envista, Carestream Dental, Nakanishi, and A-dec.
The global dental equipment market is projected to grow from USD 8.31 billion in 2026 to USD 11.48 billion by 2031, registering a 5.5% CAGR. Growth is driven by rising oral health disorders, demand for cosmetic and preventive dentistry, dental tourism, and adoption of digital imaging, CAD/CAM, intraoral scanners, laser dentistry, and 3D printing. Therapeutic dental equipment will hold the largest market share, while hospitals and clinics remain the leading end users. The US is expected to record North America’s fastest growth. Key players include Dentsply Sirona, Planmeca, Align Technology, Envista, Carestream Dental, Nakanishi, and A-dec.
Sep 30 · 09:08·GlobeNewswire